Trelagliptin succinateDPP-4 inhibitor CAS# 1029877-94-8 |
- Thrombin Receptor Agonist Peptide
Catalog No.:BCC3950
CAS No.:137339-65-2
- SLIGRL-NH2
Catalog No.:BCC3947
CAS No.:171436-38-7
- TFLLR-NH2
Catalog No.:BCC3948
CAS No.:197794-83-5
- AY-NH2
Catalog No.:BCC3949
CAS No.:352017-71-1
- ML161
Catalog No.:BCC3642
CAS No.:423735-93-7
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 1029877-94-8 | SDF | Download SDF |
| PubChem ID | 44183569 | Appearance | Powder |
| Formula | C22H26FN5O6 | M.Wt | 475.47 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | SYR-472 succinate | ||
| Solubility | DMSO : ≥ 50 mg/mL (105.16 mM) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | 2-[[6-[(3R)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxopyrimidin-1-yl]methyl]-4-fluorobenzonitrile;butanedioic acid | ||
| SMILES | CN1C(=O)C=C(N(C1=O)CC2=C(C=CC(=C2)F)C#N)N3CCCC(C3)N.C(CC(=O)O)C(=O)O | ||
| Standard InChIKey | OGCNTTUPLQTBJI-XFULWGLBSA-N | ||
| Standard InChI | InChI=1S/C18H20FN5O2.C4H6O4/c1-22-17(25)8-16(23-6-2-3-15(21)11-23)24(18(22)26)10-13-7-14(19)5-4-12(13)9-20;5-3(6)1-2-4(7)8/h4-5,7-8,15H,2-3,6,10-11,21H2,1H3;1-2H2,(H,5,6)(H,7,8)/t15-;/m1./s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Trelagliptin(SYR-472) is a long acting dipeptidyl peptidase-4 (DPP-4) inhibitor that is being developed for the treatment of type 2 diabetes (T2D).
IC50 value:
Target: DPP4
Two Phase II clinical studies have been completed with Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus. Phase III clinical studies with trelagliptin in Japan to evaluate its safety and efficacy in a once-weekly oral treatment regimen. Currently, all available DPP-4 inhibitors are dosed once-daily. A once-weekly treatment, such as trelagliptin, would provide patients with a convenient treatment alternative and has the potential to improve treatment compliance. References: | |||||
Trelagliptin succinate Dilution Calculator
Trelagliptin succinate Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.1032 mL | 10.5159 mL | 21.0318 mL | 42.0636 mL | 52.5796 mL |
| 5 mM | 0.4206 mL | 2.1032 mL | 4.2064 mL | 8.4127 mL | 10.5159 mL |
| 10 mM | 0.2103 mL | 1.0516 mL | 2.1032 mL | 4.2064 mL | 5.258 mL |
| 50 mM | 0.0421 mL | 0.2103 mL | 0.4206 mL | 0.8413 mL | 1.0516 mL |
| 100 mM | 0.021 mL | 0.1052 mL | 0.2103 mL | 0.4206 mL | 0.5258 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Trelagliptin is a long acting dipeptidyl peptidase-4 (DPP-4) inhibitor that is being developed for the treatment of type 2 diabetes (T2D). Two Phase II clinical studies have been completed with Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus. Phase III clinical studies with trelagliptin in Japan to evaluate its safety and efficacy in a once-weekly oral treatment regimen. Currently, all available DPP-4 inhibitors are dosed once-daily. A once-weekly treatment, such as trelagliptin, would provide patients with a convenient treatment alternative and has the potential to improve treatment compliance.
- INCB28060
Catalog No.:BCC3793
CAS No.:1029712-80-8
- Scutellaric acid
Catalog No.:BCN5843
CAS No.:102919-76-6
- MDL 73005EF hydrochloride
Catalog No.:BCC6636
CAS No.:102908-60-1
- Pexidartinib (PLX3397)
Catalog No.:BCC6405
CAS No.:1029044-16-3
- 17-Hydroxy sprengerinin C
Catalog No.:BCN2755
CAS No.:1029017-75-1
- Lycopsamine
Catalog No.:BCN1999
CAS No.:10285-07-1
- Intermedine
Catalog No.:BCN1997
CAS No.:10285-06-0
- MLN8237 (Alisertib)
Catalog No.:BCC2166
CAS No.:1028486-01-2
- Ganolactone B
Catalog No.:BCN2872
CAS No.:1028449-53-7
- Moracin P
Catalog No.:BCN3289
CAS No.:102841-46-3
- Mulberroside C
Catalog No.:BCN6344
CAS No.:102841-43-0
- Mulberroside A
Catalog No.:BCN6343
CAS No.:102841-42-9
- H-DL-Phg-OH
Catalog No.:BCC3317
CAS No.:103-01-5
- Monobenzone
Catalog No.:BCC3818
CAS No.:103-16-2
- Methyl cinnamate
Catalog No.:BCN5043
CAS No.:103-26-4
- Ethyl cinnamate
Catalog No.:BCN5044
CAS No.:103-36-6
- Benzyl cinnamate
Catalog No.:BCN5042
CAS No.:103-41-3
- Scutebarbatine M
Catalog No.:BCN8327
CAS No.:960302-92-5
- N-Methylbenzylamine
Catalog No.:BCN1790
CAS No.:103-67-3
- Phenylacetic Acid
Catalog No.:BCC8349
CAS No.:103-82-2
- 4'-Methylacetanilide
Catalog No.:BCC8714
CAS No.:103-89-9
- Acetaminophen
Catalog No.:BCC5269
CAS No.:103-90-2
- Dehydroheliobuphthalmin
Catalog No.:BCN5844
CAS No.:103001-05-4
- Alterlactone
Catalog No.:BCN7261
CAS No.:1030376-89-6
Identification, characterization and HPLC quantification of process-related impurities in Trelagliptin succinate bulk drug: Six identified as new compounds.[Pubmed:27209451]
J Pharm Biomed Anal. 2016 Sep 5;128:18-27.
A sensitive, selective and stability indicating reversed-phase LC method was developed for the determination of process related impurities of Trelagliptin succinate in bulk drug. Six impurities were identified by LC-MS. Further, their structures were characterized and confirmed utilizing LC-MS/MS, IR and NMR spectral data. The most probable mechanisms for the formation of these impurities were also discussed. To the best of our knowledge, six structures among these impurities are new compounds and have not been reported previously. The superior separation was achieved on an InertSustain C18 (250mmx4.6mm, 5mum) column in a gradient mixture of acetonitrile and 20mmol potassium dihydrogen phosphate with 0.25% triethylamine (pH adjusted to 3.5 with phosphate acid). The method was validated as per regulatory guidelines to demonstrate system suitability, specificity, sensitivity, linearity, robustness, and stability.
